Morning Brief — Friday, September 25, 2026

Market Overview

The dominant story today is Anthropic’s $11.6 billion, seven-year cloud infrastructure deal with Akamai — the largest in Akamai’s history — which is reshaping how the market prices “surprise AI beneficiaries” and rippling across adjacent names in CDN, compute, and edge infrastructure. Treasury yields remain stubbornly elevated (30-year hitting fresh long-term highs), keeping rate-sensitive growth under pressure, while Manufacturing PMI at 57.0 and Services PMI at 58.7 signal a robust economy that simultaneously argues against near-term Fed cuts. The macro backdrop is classic late-cycle tug-of-war: strong growth data vs. yield anxiety, with AI deal flow continuing to provide stock-specific escape velocity for select names.

Claude’s Call

UP — but barely, and with significant dispersion. The Anthropic-Akamai deal injects genuine animal spirits into AI infrastructure names, and the biotech/genomics cohort is catching its own bid on GRAL’s FDA momentum and MRNA’s oncology repricing. The S&P likely grinds marginally positive today on these pockets of strength, but elevated yields and a pre-weekend risk-off impulse cap the upside; expect tech heavyweights to drag while AI-adjacent mid-caps carry the day.

Top Movers

AKAM (+12.82%) — $124.57 → $133.52 (+7.2% upside) Thesis: This is a real catalyst — not sector sympathy, not a vague AI mention. Anthropic signed a $11.6 billion, 7-year committed contract making Akamai a primary AI compute infrastructure partner, a deal Piper Sandler says could flip Akamai’s identity from value CDN stock to hypergrowth cloud platform by 2028. The market was completely unprepared for this; AKAM has traded as a slow-growth, mature CDN business for years, and a forward P/E of ~18x vs. a peer median of ~40x means there’s legitimate re-rating room as analysts scramble to revise models. BofA’s concurrent AMD price-target hike citing the CPU/agentic AI angle adds sector validation. Technically, shares broke out of a multi-month consolidation and are sitting right at the 50% fib retracement level ($124.99) — this is actually a clean entry zone, not a chase, because the stock still has the 38.2% fib resistance at $133.52 and the 23.6% at $144.08 as near-term targets with clear distance to travel. Levels: Exit at $133.52 (fib 38.2% resistance). Support at $113.48 (50-day SMA) — a close below this invalidates the breakout thesis.

GRAL (+15.38%) — $125.21 → $146.86 (+17.3% upside) Thesis: FDA Medical Devices Advisory Committee voted in favor of Grail’s Galleri multi-cancer early detection test — this is a binary de-risking event that genuinely changes the commercialization timeline for a technology that addresses a massive unmet clinical need. PATHFINDER 2 data in Nature Medicine provided the clinical foundation, and the adcom vote is the regulatory bridge toward potential approval and Medicare coverage discussions. The 56.6% weekly gain looks scary, but the catalyst is real and durable — this isn’t a one-day pop, it’s a re-rating event. That said, the RSI at 56.85 on a near-$125 stock that was at $45 six months ago tells you momentum is strong but not yet frothy. Technically, the stock is at its 6-month high with the 1.272 fib extension at $146.86 as the next logical target. Levels: Exit at $146.86 (fib 1.272 extension). Support at $106.43 (fib 23.6%) — a break back below $106 would signal the FDA catalyst is being faded and the trade is over.

TWST (+16.11%) — $184.03 → $222.32 (+20.8% upside) Thesis: Leerink called Twist the “single most important beneficiary” of Anthropic’s expanding biology research push — which is a bold claim, but the Lilly TuneLab partnership announced September 16 gives it concrete commercial grounding. Twist supplies synthetic DNA and antibody characterization data that AI-driven drug discovery platforms need at scale; if Anthropic is building out biology-focused AI, TWST is a picks-and-shovels play on that trend rather than a direct AI bet. The 493% 52-week gain is obviously eye-popping, and the stock is at its 6-month high with no 200-day SMA to anchor valuation — but the fib 1.272 extension at $222.32 is achievable if the Anthropic biology narrative sustains into next week. Be honest about the risk here: the RSI was already elevated at 72+ before today’s move, and Martin Shkreli’s public short call plus analyst consensus targets well below current price are real headwinds. This is a trade, not an investment. Levels: Exit at $222.32 (fib 1.272 extension). Support at $150.81 (fib 23.6%) — that’s a 18% drawdown from here, so position size accordingly.

MRNA (+6.98%) — $194.82 → $237.68 (+22.0% upside) Thesis: Three overlapping catalysts are driving this repricing: (1) CEO Stéphane Bancel’s UNGA commentary projecting confidence in oncology diversification beyond COVID, (2) investment talks with UAE sovereign wealth (capital injection optionality), and (3) Phase 3 melanoma data for intismeran autogene due at ESMO on October 24 — a hard, near-term binary event that traders are pre-positioning for. The stock went from $63 to $195 in two months, and the consensus mean target of $120 is 39% below current price, meaning the street is either asleep or the thesis is getting well ahead of fundamentals. The ESMO readout is the make-or-break moment: positive data = continued re-rating toward $237 fib extension; negative = violent unwind back toward $160 support. Technically, the stock is at its 6-month high with the 23.6% fib support at $160 as the nearest backstop — there’s nothing in between that price and current levels. Levels: Exit at $237.68 (fib 1.272 extension) before ESMO on Oct 24. Support at $160.88 (fib 23.6%) — treat this as your hard stop.

CDNA (+13.0%) — $61.37 → $74.46 (+21.3% upside) Thesis: BTIG raised its price target from $60 to $74 after hosting CareDx management in Boston, with management sounding confident post the positive resolution of the transplant local coverage determination (LCD) dispute — this is the key fundamental unlock. The LCD resolution removes a major reimbursement overhang that had been suppressing transplant testing volumes, and the management tone shift from defensive to confident is exactly the signal you want to see ahead of a potential acceleration quarter. The RSI at 31.71 is actually oversold despite today’s 13% gain — meaning the stock was deeply depressed before this move and there’s genuine mean-reversion fuel. Technically, the stock broke out to a 6-month high; fib 1.272 extension at $74.46 aligns almost perfectly with BTIG’s new target, creating a clean, analyst-validated exit level. Levels: Exit at $74.46 (fib 1.272 extension, BTIG target). Support at $51.13 (fib 23.6%) and $47.52 (50-day SMA).

CBRL (+9.09%) — $51.84 → $55.66 (+7.4% upside) Thesis: Earnings beat on non-GAAP EPS ($0.99 reported vs. consensus estimates) and revenue came in ahead of expectations at $849.3M, though sales were still down 2.2% YoY — this isn’t a growth story, it’s a margin recovery story. Menu initiatives and operational efficiency gains are doing the heavy lifting, and management’s full-year guidance at $3.36B midpoint was only slightly below consensus (0.8%). The 9% reaction feels roughly justified given how depressed this stock was — it was at $26 at its 6-month low. The risk is that guidance came in light of consensus, meaning this could be a “sell the news” setup rather than the start of a new uptrend. Technically, the stock is testing right below its 50-day SMA at $53.79 — a clean close above that level would confirm the breakout; failure there is a warning. Levels: Exit at $55.66 (20-day high/resistance). Support at $51.33 (fib 23.6%).

NBIS (+7.44%) — $243.48 → $286.69 (prior 6-month high, +17.7% upside) Thesis: BNP Paribas upgraded with a dramatically higher price target citing $22B ARR potential by 2027, and the GPU price hike announcement next week signals Nebius has pricing power that supports the bull thesis. The Palantir strategic partnership (Sept 8) adds enterprise distribution credibility. However, Michael Burry’s expanded short position is not something to dismiss — Burry shorts with size and conviction, and he’s specifically targeting AI infrastructure names he believes are overvalued on capex assumptions. The technical setup is mixed: trading near 20-day highs but well below the 6-month high of $286.69, with the fib 23.6% support at $240.80 immediately below — one bad day and it’s testing that level. This is a high-conviction bull vs. bear standoff. Levels: Exit at $286.69 (6-month prior high). Support at $240.80 (fib 23.6%) — uncomfortably close to current price.

Headlines to Watch

  • Akamai-Anthropic $11.6B Cloud Deal — The most important story of the day; it forces a fundamental re-evaluation of which legacy tech companies have latent AI infrastructure value, and the ripple effects on CoreWeave, Cloudflare, and Fastly are worth monitoring for sympathy continuation or rotation.

  • GRAIL FDA Advisory Committee Vote — A positive adcom vote for Galleri sets the stage for formal FDA approval and eventual Medicare coverage determination; if CMS moves toward reimbursement, this becomes a multi-year commercial ramp story that pulls ILMN and TXG higher as multi-cancer detection ecosystem beneficiaries.

  • Moderna ESMO October 24 Catalyst — The Phase 3 melanoma data readout for intismeran autogene is the single most important binary event in biotech for Q4 2026; the stock’s 23% weekly gain means a miss gets punished severely — flag your calendar and trim into strength if the trade works.

  • Treasury Yields at Multi-Year Highs — The 30-year yield hitting its highest level since 2007 is the macro tax on every growth/duration trade; if yields continue spiking, the AI re-rating story faces a valuation ceiling regardless of deal flow quality.

  • Michael Burry Expands Short on NBIS and AI Infrastructure Peers — Burry’s short expansion against Nebius and adjacent AI infrastructure names is a direct challenge to the neocloud bull thesis; worth tracking whether institutional positioning follows his lead over the coming weeks.

  • MGM Potentially Bidding for People Inc. (PPLI) — A classic M&A arbitrage setup; if confirmed, this is a clean 10-15% pop play with limited downside to deal-spread compression, though Barry Diller-controlled assets historically come with complex negotiations.

  • Manufacturing PMI 57.0 / Services PMI 58.7 — These are blowout readings that confirm the economy is running hot — good for cyclicals and earnings revisions, bad for rate-cut hopes and bond proxies; lean into the growth/quality trade and out of utilities and long-duration growth.

Claude’s Top Picks

AKAM (+12.82% today, +19.18% week) — $124.57 → $133.52 (+7.2% upside) Valuation: Forward P/E of 17.8x vs. peer median of 40.6x makes AKAM one of the most compelling re-rating setups in tech — the market simply hasn’t priced it as an AI infrastructure name yet. Upside: A committed 7-year, $11.6B contract with Anthropic gives analysts a hard revenue figure to model, and the first estimate revisions will likely push the stock significantly higher over the next 2 weeks as sell-side scrambles to update models. Risk: Akamai still has to execute operationally on AI infrastructure at scale — any sign the company lacks the technical capability to fulfill this contract would crater the thesis immediately.

GRAL (+15.38% today, +56.61% week) — $125.21 → $146.86 (+17.3% upside) Valuation: No comp data available, but this is a pre-revenue/early-commercial biotech being repriced as a platform play — valuation is less relevant than milestone progression at this stage. Upside: FDA adcom support is the penultimate step before full approval; once approved, Medicare coverage determination and national rollout of Galleri creates a multi-billion-dollar TAM that the current market cap doesn’t fully reflect. Risk: The 56% weekly move means a lot of good news is priced in — any pushback from CMS on reimbursement or a delayed full FDA approval decision could trigger a sharp 20-30% reversal.

CDNA (+13.0% today, +13.06% week) — $61.37 → $74.46 (+21.3% upside) Valuation: No comp data provided, but the RSI at 31.71 pre-move signals this stock was genuinely oversold — the BTIG $74 target provides a credible, analyst-validated upside level. Upside: LCD resolution removes the key reimbursement overhang that suppressed transplant testing volumes, and with management displaying renewed confidence in investor meetings, the stage is set for a guidance raise on the next earnings call. Risk: The volume ratio is only 1.0 (average), meaning conviction behind today’s move is not yet exceptional — if volume doesn’t pick up next week, the move may fade without follow-through buying.

MRNA (+6.98% today, +23.25% week) — $194.82 → $237.68 (+22.0% upside) Valuation: Street consensus target of $120 is 39% below current price, suggesting the market is pricing in ESMO success that analysts haven’t yet incorporated — this is a momentum trade into a known catalyst, not a valuation play. Upside: The ESMO October 24 melanoma readout is a hard catalyst with real probability of positive data based on Phase 2 signals, and UAE sovereign investment discussions suggest non-U.S. capital formation interest that adds optionality. Risk: The mean analyst target of $120 vs. current $195 means the stock falls 38% back to consensus on a negative ESMO readout — this is a high-conviction, time-limited trade that must be managed tightly.

TEM (+7.38% today, +2.34% week) — $82.24 → $93.31 (+13.5% upside) Valuation: No comp data, but Goldman initiated at Neutral with a $75 target — this stock is trading above the Goldman target, meaning the smart-money view is already slightly cautious. Upside: The ARPA-H heart failure AI contract, genomic profiling revenue growth, and positioning as one of the key “AI-powered medical” picks for Q4 creates multiple near-term catalysts; fib 1.272 extension at $93.31 is achievable on continued sector momentum. Risk: The Chief Accounting Officer sold $529K of stock this week following a 30% YTD rebound — insider selling at the highs is a yellow flag, and Goldman’s Neutral reflects real contract renewal risk in the data licensing business over the next two years.

Avoid

TWST — Up 493% in 52 weeks, RSI was already in overbought territory before today’s 16% move, no 200-day SMA exists as a valuation anchor, analyst consensus targets are well below current price, and a high-profile short seller (Shkreli) is publicly on the other side — the Anthropic biology story is real but the risk/reward at $184 for a company still burning cash is poor for new entries today.

LU — A $1.35 stock with an RSI of 1.21 (effectively zero), a 15.5% revenue decline, governance instability with four senior director exits including the CFO, and pre-tax profit declining despite the headline loss narrowing via tax benefits — this is a value trap with serious structural problems masquerading as a turnaround play; the 10.6% daily move is noise, not signal.

BLLN — CEO liquidated his entire directly-held stake for $3M and the SVP sold additional shares shortly after — dual insider liquidations at the highs, ahead of a 30% YTD gain, with volume ratios far below average suggesting the move lacks conviction. Jim Cramer calling it a “pretty darn good company” is not a buy catalyst. Pass.

WSB Sentiment Check

META — WSB says: BULLISH (80% bullish) Claude says: AGREE — The AI Muse buzz is real, the month-long run has fundamental backing in ad revenue acceleration and AI monetization, and at $755 the stock is 3% below its 6-month high of $777 with the fib 1.272 extension at $846 as a realistic near-term target; 80% bullish WSB consensus on a stock with genuine earnings power is one of the rare times the crowd is right.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — MU at $1,104 is well off its 6-month high of $1,213, sitting between the 23.6% fib support ($1,002) and prior highs; AI-driven HBM demand is real and the bull case is intact, but the stock’s 3-year low-to-high magnitude means there’s genuine valuation debate at these levels. The mixed WSB sentiment reflects real uncertainty — this isn’t delusional, it’s honest.

AMD — WSB says: MIXED (55% bullish) Claude says: AGREE — AMD at $635 is at a 6-month high with the BofA price target hike (citing the Anthropic-Akamai deal’s CPU/agentic AI implications) providing fresh fundamental backing today; technically clean breakout with the 1.272 fib extension at $754 as the next target. The mixed sentiment is fair given the stock’s 224% run from its 6-month low — momentum is strong but not universally loved, which is actually a healthier setup than euphoric consensus.

NBIS — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — BNP Paribas upgrade to $22B ARR by 2027 and GPU price hikes are real catalysts, but Michael Burry’s expanded short is not something 80% bullish WSB sentiment is adequately pricing in. The fib 23.6% support at $240.80 is 1% below current price — if Burry’s thesis gains traction, the stock has a long way to fall. This is a legitimate bull vs. smart-bear standoff; the WSB crowd is right on the direction but dangerously underweight on risk.

SNDK — WSB says: MIXED (55% bullish) Claude says: DISAGREE (lean bearish) — SNDK at $1,797 is well below its 6-month high of $2,335 and sitting below the 23.6% fib retracement at $1,919, which has now become resistance. The stock has failed to recover that level and the downtrend from $2,335 is technically intact. Mixed WSB sentiment on a stock that’s 23% off its highs with no clear near-term catalyst feels like bottom-fishing in a declining name; there are better places to deploy capital in the semiconductor space today.

Earnings Scorecard

CBRL — BEAT on EPS ($0.99 non-GAAP actual vs. consensus estimates); Revenue Beat vs. expectations | Stock: +9.09% | Reported: Q2 CY2026 The EPS beat was substantial and margin improvement from menu initiatives/operational gains is a genuine positive inflection, but revenue still declined 2.2% YoY and full-year guidance came in 0.8% below consensus — the +9% reaction is modestly overdone for a business that’s still shrinking the top line; this is a trading pop, not the start of a structural re-rating. Fade the rip above the 50-day SMA at $53.79.

SNX — BEAT on EPS ($12.58 actual); Record billings up 40% | Stock: +4.4% | Reported: Q3 2026 TD SYNNEX delivered a blowout quarter with 40% billing growth driven by AI infrastructure distribution and Hyve strength — the +4.4% reaction looks insufficient given the magnitude of the beat; this name deserves follow-through buying and the mild reaction suggests it’s under-covered, not over-valued.

COST — BEAT on EPS ($19.90 actual); Comp sales growth lagged | Stock: +1.3% | Reported: Q4 2026 Costco beat EPS (aided by a tariff refund, worth noting), but comparable sales growth lagging consensus is the tell — the muted +1.3% reaction is justified; this is a quality-compounder that rarely surprises to the upside, and the tariff refund benefit is non-recurring.

CTAS — BEAT on EPS ($5.06 actual); Revenue Beat; Margin gains | Stock: +1.07% | Reported: Q1 2027 Clean beat driven by uniform services demand and margin discipline — the +1.07% reaction is slightly insufficient for the quality of the beat, but Cintas trades at premium multiples that limit upside surprise reactions. Hold if you own it; not compelling as a new entry at these levels.

AZO — BEAT on EPS ($146.24 actual); Sales Miss | Stock: +0.92% | Reported: Q4 FY2026 EPS beat was bolstered by tariff refunds (same as Costco — note the pattern) while revenue missed consensus; the aging vehicle fleet thesis remains intact as a long-term tailwind, but the +0.92% reaction is appropriate given the revenue miss. Not a catalyst worth chasing.

GIS — EPS of -$1.64 (loss); Revenue in-line | Stock: -0.72% | Reported: Q1 FY2027 General Mills reporting a net loss while flagging innovation and inflation dynamics is a “show me” story at best — the -0.72% reaction is too mild given an EPS loss; there’s likely more downside pressure as the market digests the full context of innovation costs vs. volume trends. Avoid.

BB — BEAT on EPS ($0.10 actual); Record QNX revenue; Guidance raised | Stock: +0.23% | Reported: Q2 FY2027 BlackBerry’s QNX automotive software delivering record revenue with a full-year guidance raise is genuinely positive, but the market’s +0.23% reaction reflects the stock’s identity crisis — nobody knows whether to value it as a security software company or automotive tech name. The reaction was insufficient for a guidance raise, suggesting this is a sleeper with a potential delayed pop as the automotive software angle gets more attention in Q4.

ABVX — EPS of -$6.17 (loss) | Stock: -1.53% | Reported The -1.53% decline on a reported loss is benign for a pre-profitability biotech; the market is treating this as a known cash-burn situation rather than a surprise. Hold if you’re in the thesis; not actionable today.

This brief is for informational purposes only and does not constitute investment advice. All levels and targets are based on technical analysis and publicly available information. Past performance does not guarantee future results.